An elderly woman who is smiling because she was part of a successful clinical trial for a new drug that can slow Parkinson's Disease

Treating Parkinson’s Disease Through a New Metabolic Lens

Andarta Therapeutics is developing a novel therapeutic approach designed to address Parkinson's unmet need.

Our lead program, AND-0765, is being developed with the goal of slowing the progression of Parkinson’s disease, rather than simply managing symptoms.

Our lead program, AND-0765, is being developed with the goal of slowing the progression of Parkinson’s disease, rather than simply managing symptoms.

The fattyacidopathy hypothesis proposes that dysregulated fatty acid metabolism plays an important role in driving the pathological processes underlying Parkinson’s disease. Alterations in lipid synthesis and handling may contribute to neuronal dysfunction, mitochondrial stress, and neurodegeneration.

By targeting FASN, AND-0765 is designed to correct these metabolic abnormalities and potentially modify disease biology at its root.

A group of scientists studying the use of lipidopathy for use in drug development for Parkinson's Disease

An elderly couple happy because they have beaten Parkinson's Disease

AND-0765 is a novel small-molecule drug candidate that has not yet been tested in humans. Andarta Therapeutics plans to initiate clinical trials in 2026, marking an important step toward translating this new scientific insight into a potential disease-modifying therapy for people living with Parkinson’s disease.